Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Japan's Takeda eyes new focus on vaccines after OTC asset sales - CEO

11/05/2020 | 10:33pm EST
FILE PHOTO: Takeda Pharmaceutical Co President and Chief Executive Officer Christophe Weber attends an opening ceremony for its new headquarters in Tokyo

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber said.

Japan's biggest drugmaker by revenue recently completed $10 billion in sales of mostly over-the-counter drug assets to reduce debt after its $59 billion purchase of Shire, saying it would focus on five key business areas.

With a dengue fever vaccine in development and deals to make and distribute COVID-19 vaccines in Japan, the company could add a new pillar to its business lineup, Weber said.

"We are in the vaccines business," Weber told Reuters in an interview. "If the dengue vaccine is successful, yes, it would be a sixth one."

Takeda's current five core businesses are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

The company looked into making a COVID-19 vaccine, but determined with its mix of technology and capacity, it was a better fit to work with other developers, Weber said.

Takeda agreed last month to distribute 50 million doses of Moderna Inc's COVID-19 vaccine in Japan. That was on top of a previous deal to produce Novavax Inc's COVID-19 candidate, aiming to make 250 million doses.

Takeda's dengue vaccine candidate, TAK-003, is on track for regulatory filing in Asia, Latin America, and the European Union by the end of fiscal 2020, the company said last month. The disease is spread by mosquitoes and is estimated to affect 50 million people a year worldwide with 22,000 deaths.

Following the Shire takeover, Takeda reached its asset disposal goal with the sale of its Japanese consumer healthcare business to Blackstone Group for 242 billion yen ($2.31 billion) announced in August.

The company was not eyeing any more major sell offs, Weber said, saying any such deals would be "very marginal."

(Reporting by Rocky Swift; editing by Jane Wardell)

By Rocky Swift


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 7.79% 133.74 Delayed Quote.19.79%
NOVAVAX, INC. 1.70% 126.45 Delayed Quote.14.79%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.11% 3591 End-of-day quote.-4.37%
THE BLACKSTONE GROUP INC. 0.75% 65.76 Delayed Quote.0.63%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09:30aMODERNA : Says First Participant Dosed in COVID-19 Vaccine Phase 1/2 Study in Ja..
MT
08:58aTAKEDA PHARMACEUTICAL : Clinical study begins in Japan for Moderna's COVID-19 va..
AQ
01/20TAKEDA PHARMACEUTICAL : Brazil antitrust regulator clears hurdle for Hypera-Take..
RE
01/19TAKEDA PHARMACEUTICAL : Gets Canadian Regulatory Approval for Maintenance Treatm..
MT
01/19TAKEDA PHARMACEUTICAL : to Hold Investor Call on January 29 During World Confere..
PU
01/13TAKEDA PHARMACEUTICAL : KSQ Therapeutics Join Hands to Develop, Commercialize Ca..
MT
01/11Drug makers help Nikkei scale fresh 3-decade high
RE
01/11TAKEDA PHARMACEUTICAL : Projects 50% Surge in Revenue Growth Over Coming Decade;..
MT
01/11TAKEDA PHARMACEUTICAL : Provides Pipeline Update and Shares Goal to Increase Rev..
BU
01/11TAKEDA PHARMACEUTICAL : to Present at The 39th Annual J.P. Morgan Healthcare Con..
BU
More news
Financials
Sales 2021 3 232 B 31 220 M 31 220 M
Net income 2021 201 B 1 938 M 1 938 M
Net Debt 2021 3 840 B 37 099 M 37 099 M
P/E ratio 2021 34,1x
Yield 2021 5,01%
Capitalization 5 614 B 54 184 M 54 231 M
EV / Sales 2021 2,93x
EV / Sales 2022 2,73x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 216,67 JPY
Last Close Price 3 591,00 JPY
Spread / Highest target 81,0%
Spread / Average Target 45,3%
Spread / Lowest Target 14,2%
EPS Revisions
Managers and Directors
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-4.37%54 244
JOHNSON & JOHNSON3.18%427 472
ROCHE HOLDING AG3.56%308 129
NOVARTIS AG2.82%219 666
MERCK & CO., INC.0.81%208 627
PFIZER INC.-0.84%202 881